Federal Policy Shifts on Medical Cannabis Access for Veterans
In May 2026 the U.S. House of Representatives approved amendments that would enable Department of Veterans Affairs physicians to issue medical cannabis recommendations directly to eligible veterans. The change, reported by Marijuana Moment on May 15, 2026, seeks to streamline access for former service members who often turn to cannabis for conditions such as chronic pain, PTSD, and sleep disorders.
The same legislative package also included provisions to increase awareness of psychedelic therapies, reflecting a broader congressional interest in alternative treatments for veteran‑specific health challenges.
Concurrently, the House Appropriations Committee passed a spending bill containing a rider that would block the Department of Justice from pursuing rescheduling of marijuana under the Controlled Substances Act. While this signals continued federal resistance to broad cannabis reform, the bill retains a longstanding protection that shields state‑level medical cannabis programs from federal interference, preserving the current patchwork of state laws.
Additional federal developments noted in the same period include:
- A U.S. Bankruptcy Court judge approving the recognition of insolvency proceedings for Cannabist Co., a step that could affect the company’s restructuring efforts.
- Senator Susan Collins (R‑ME) questioning FBI Director Kash Patel and DEA Administrator Terrance Cole during a Senate Appropriations Committee hearing about strategies to curb illicit marijuana operations linked to overseas actors in Maine and other states.
- A House bill focused on regulating hemp products gaining an additional cosponsor, bringing total support to six members, indicating gradual progress for the industrial hemp sector.
State‑Level Regulatory and Prescribing Updates
State governments continue to refine medical cannabis policies, often responding to patient needs and clinical evidence.
Louisiana Expands Hospital Use
The Louisiana House Health and Welfare Committee approved a Senate‑passed bill that would allow patients with terminal or irreversible conditions to use medical marijuana within hospitals, subject to strict safety and dosing limits. The measure aims to improve comfort and symptom management for critically ill individuals receiving inpatient care.
Enforcement and Research Activities
- The New Jersey State Board of Medical Examiners temporarily suspended the license of a physician who allegedly failed to meet state requirements for authorizing medical cannabis.
- New York regulators are recruiting participants for a study examining the effects of CBD and THC on inflammatory bowel disease, adding to the growing clinical data set on cannabinoid therapeutics.
- Michigan regulators opened a second public comment period on proposed revisions to marijuana licensing and operational rules.
- Colorado’s marijuana regulators published updated guidance on fee structures for cultivation, testing, and retail licenses.
- Nevada released a demographic study detailing ownership, employment, and consumer trends within its cannabis industry.
- Oklahoma removed a member from its Medical Marijuana Executive Advisory Council amid routine board rotations.
Australian Policy and Global Research Insights
Internationally, Australia’s Victoria Legislative Council passed a measure to formalize the use of cautions rather than arrests for minor marijuana offenses. The shift reflects a move toward harm‑reduction approaches while maintaining public safety objectives.
In the research arena, a study highlighted by Marijuana Moment found that CBD treatment produced statistically and clinically significant improvements in quality‑of‑life scores for children with drug‑resistant epilepsy, with a majority of participants experiencing reduced seizure frequency. Separately, a case series suggested that psilocybin may aid motor recovery and sensory integration in individuals with incomplete spinal cord injury, pointing to potential therapeutic avenues for other regulated substances.
Corporate Earnings, Legal Actions, and Market Developments
The cannabis sector continues to navigate financial performance, corporate restructuring, and legal scrutiny.
- Glass House Brands Inc. reported quarterly net revenue of $40.5 million and a net loss of $17 million, underscoring the ongoing pressure on profitability amid competitive pricing and regulatory costs.
- Auxly Cannabis Group Inc. posted quarterly net revenue of C$39.8 million.
- Trulieve Cannabis Corp. is seeking shareholder approval to redomicile the company from British Columbia, Canada, to Delaware, a move intended to streamline corporate governance and access to U.S. capital markets.
- Stiiizy faces a lawsuit alleging that concealed tracking tools on its website were used to monitor consumer shopping habits and subsequently sell that data to third‑party brokers.
- California’s Attorney General highlighted enforcement actions against an unlicensed marijuana business, reinforcing state efforts to curb the illicit market while supporting licensed operators.
These developments illustrate the evolving interplay between federal policy, state innovation, scientific inquiry, and industry dynamics as stakeholders work to define safe, equitable, and evidence‑based pathways for cannabis and cannabinoid‑based therapies.
Sources: Marijuana Moment (May 15, 2026), U.S. House of Representatives legislative records, state regulatory filings, company earnings releases, and court documents.
For the original report, see: Here
